CORDLIFE GROUP LIMITED (P8A) fair value: what the stock is really worth
As of Sep 29, 2026: fair value of CORDLIFE GROUP LIMITED S$0.20, price S$0.12, upside +65.3%, quality 47 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch CORDLIFE GROUP LIMITED for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range 0.1080 SGD – 0.5550 SGD · fair‑value band 0.1500 SGD – 0.3000 SGD · the 0.1210 SGD price screens below the 0.2000 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow CORDLIFE GROUP in your weekly email
Every Wednesday you see whether CORDLIFE GROUP is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Cordlife GrouCordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, the Philippines, and internationally. It operates in two segments, Banking and Diagnostics.
Show more
Cordlife GrouCordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, the Philippines, and internationally. It operates in two segments, Banking and Diagnostics. The Banking segment collects, processes, banks, and tests biological materials, such as cord blood, lining, and tissue samples. The Diagnostics segment offers diagnostic testing services, such as newborn genetic and metabolic screenings; pediatric vision and ear screenings; pediatric allergen test; and genetic talent test services. The company also provides corneal lenticule banking, and lifestyle genetic screening services for adults. In addition, it offers life sprouts, medical laboratory, marketing, and property investment services, as well as medical and pharmaceutical research and development and consulting services. Cordlife Group Limited was incorporated in 2001 and is based in Singapore.
Stock analysis
CORDLIFE GROUP LIMITED (P8A) currently trades at 0.1210 SGD, while our model-based Fair Value estimate is 0.2000 SGD, implying the stock looks roughly 39.5% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: 0.1500 SGD (bear) to 0.3000 SGD (bull), the price of 0.1210 SGD sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
CORDLIFE GROUP LIMITED reported revenue of 38.9M SGD in FY2025 versus 56.7M SGD in FY2021, a compound −9.0%/yr. Reported net income was −12.6M SGD in FY2025.
Key figures
Market cap 39.7M SGD (≈ $31.0M) · P/S ratio 1.04 · EPS (TTM) −0.0500 SGD · Dividend yield 0.2% · Net margin −32.5% · Return on equity −11.5% · Return on assets (EBIT) −3.3% · Operating margin −25.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 33 out of 100 (low confidence).
What moves the price
The share trades about 44% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at 65%, P8A screens cheaper than that median.
Fair Value models
Bear 0.1500 SGDFair Value 0.2000 SGDBull 0.3000 SGD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+40.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.2%
Start year 2020 (pandemic). Over 10 years: −4.2% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
14.6% (2020) → −38.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 131 stocks
Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score44 · Below median
Fair Value upside+65.3% · Top 25%
Profitability
Return on assets−4.3% · Bottom 25%
Net margin (TTM)−33.3% · Bottom 25%
Operating margin (TTM)−25.1% · Bottom 25%
Growth and dividend
Revenue growth−6.1% · Bottom 25%
Dividend yield (TTM)0.2% · Bottom 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "CORDLIFE GROUP LIMITED Fair Value". https://www.fairvalue-calculator.com/stock/P8A
Frequently asked questions
Is CORDLIFE GROUP LIMITED (P8A) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of 0.2000 SGD versus a price of 0.1210 SGD, about +65% upside (undervalued).
What is the fair value of P8A?
Our model-based fair value for CORDLIFE GROUP LIMITED is 0.2000 SGD (as of Sep 27, 2026), built from audited fundamentals. The current price: 0.1210 SGD.
What is the quality score of P8A?
CORDLIFE GROUP LIMITED has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CORDLIFE GROUP LIMITED (P8A)?
Our model-based price target is the fair value of 0.2000 SGD (as of Sep 27, 2026) from 1 valuation models. Cautious scenario 0.1500 SGD, optimistic scenario 0.3000 SGD. It is a calculation from audited fundamentals, not an analyst target.
What is the CORDLIFE GROUP LIMITED stock forecast for 2026?
Our models put fair value at 0.2000 SGD, about +65% upside versus a price of 0.1210 SGD (undervalued). Cautious scenario 0.1500 SGD, optimistic scenario 0.3000 SGD. The calculation is refreshed regularly with new filings.
What is the revenue of CORDLIFE GROUP LIMITED (P8A)?
CORDLIFE GROUP LIMITED reported trailing-twelve-month revenue of about 38.3M SGD (latest available figure, as of Sep 27, 2026).
Does CORDLIFE GROUP LIMITED pay a dividend?
CORDLIFE GROUP LIMITED currently shows a dividend yield of about 0.18% relative to its recent price (as of Sep 27, 2026).
What is the intrinsic value of CORDLIFE GROUP LIMITED (P8A)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CORDLIFE GROUP LIMITED it is 0.2000 SGD per share (as of Sep 27, 2026), against a price of 0.1210 SGD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is CORDLIFE GROUP LIMITED stock overvalued or undervalued in 2026?
As of Sep 27, 2026, P8A trades below its calculated fair value: price 0.1210 SGD, fair value 0.2000 SGD, a gap of about +65% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of P8A?
No. The price is what the market pays today (0.1210 SGD); the fair value is what the company's own numbers justify (0.2000 SGD). For CORDLIFE GROUP LIMITED the two are 0.0790 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is CORDLIFE GROUP LIMITED worth?
The market values CORDLIFE GROUP LIMITED at about 39.7M SGD (market capitalisation, as of Sep 27, 2026). Per share that is 0.1210 SGD; our models calculate a fair value of 0.2000 SGD per share.
What do the bullish and bearish scenarios say about P8A?
Our models span a range for CORDLIFE GROUP LIMITED: cautious scenario 0.1500 SGD, base 0.2000 SGD, optimistic 0.3000 SGD per share (as of Sep 27, 2026, price 0.1210 SGD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CORDLIFE GROUP LIMITED (P8A)?
Balance-sheet figures for CORDLIFE GROUP LIMITED (as of Sep 27, 2026): return on equity −11.5%. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is P8A from its 52-week high?
CORDLIFE GROUP LIMITED trades at 0.1210 SGD, about 44% below its 52-week high of 0.2150 SGD and 12% above the low of 0.1080 SGD (as of Sep 29, 2026). Distance from the high says nothing about value: that is what the fair value of 0.2000 SGD is for.
Which stocks are comparable to CORDLIFE GROUP LIMITED?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CORDLIFE GROUP LIMITED stock attractive at the current price?
The data as of Sep 27, 2026: price 0.1210 SGD, calculated fair value 0.2000 SGD (+65%), Quality Score 47/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of P8A calculated?
We run CORDLIFE GROUP LIMITED through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.2000 SGD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. CORDLIFE GROUP LIMITED currently trades 40 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CORDLIFE GROUP LIMITED (P8A)?
The closing price on Sep 29, 2026 was 0.1210 SGD. Our model-based fair value is 0.2000 SGD, about +65% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CORDLIFE GROUP LIMITED right now?
The price is below even our cautious bear case (0.1500 SGD). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (47/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (0.1500 SGD to 0.3000 SGD) leaves room in how you read the outcome.
Key figures of CORDLIFE GROUP LIMITED
How large is the market capitalisation of CORDLIFE GROUP LIMITED (P8A)?
The market capitalisation of CORDLIFE GROUP LIMITED is 39.7M SGD (≈ $31.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CORDLIFE GROUP LIMITED (P8A)?
The price-to-sales ratio of CORDLIFE GROUP LIMITED is 1.04 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CORDLIFE GROUP LIMITED (P8A)?
Earnings per share at CORDLIFE GROUP LIMITED are −0.0500 SGD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of CORDLIFE GROUP LIMITED (P8A)?
The dividend yield of CORDLIFE GROUP LIMITED is 0.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of CORDLIFE GROUP LIMITED (P8A)?
The net margin of CORDLIFE GROUP LIMITED is −32.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CORDLIFE GROUP LIMITED (P8A)?
The return on equity (ROE) of CORDLIFE GROUP LIMITED is −11.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CORDLIFE GROUP LIMITED (P8A)?
On an EBIT basis the return on assets of CORDLIFE GROUP LIMITED is −3.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CORDLIFE GROUP LIMITED (P8A)?
The operating margin of CORDLIFE GROUP LIMITED is −25.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CORDLIFE GROUP LIMITED (P8A)?
Revenue at CORDLIFE GROUP LIMITED is growing −6.1% versus a year earlier (3y avg −11.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at CORDLIFE GROUP LIMITED (P8A)?
Earnings per share at CORDLIFE GROUP LIMITED are growing −57.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does CORDLIFE GROUP LIMITED (P8A) generate?
The free cash flow of CORDLIFE GROUP LIMITED is −1.4M SGD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch CORDLIFE GROUP LIMITED in the live analysis
One click puts CORDLIFE GROUP LIMITED on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
